News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SEC Accuses Two Doctors Of Insider Trading After GTx, Inc. (GTXI) Clinical Trial Is Halted


5/20/2014 8:47:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Two San Bernardino doctors agreed to pay more than $100,000 in penalties for allegedly selling a pharmaceutical company’s stock after learning that regulators were halting a clinical trial of a prostate cancer drug they were testing. The Securities and Exchange Commission accused Dr. Franklin Chu and Dr. Daniel Lama of insider trading after they avoided significant losses by selling shares of GTx Inc. before the Memphis company disclosed it had been ordered to stop testing the drug Capesaris.

Help employers find you! Check out all the jobs and post your resume.

Read at Los Angeles Times
Read at SF Gate
Read at Market Watch

comments powered by Disqus
GTx, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES